VBIO Earnings Valion Bio, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–19 of 19
| Q2 2025 | 2025-06-30 | -4.64 | 2025-08-14 | 10-Q |
| Q1 2025 | 2025-03-31 | -2.52 | 2025-05-15 | 10-Q |
| FY 2024 | 2024-12-31 | -19.68 | 2025-03-21 | 10-K |
| Q3 2024 | 2024-09-30 | -1.07 | 2024-11-14 | 10-Q |
| Q2 2025 | 2024-06-30 | -17.05 | 2025-08-14 | 10-Q |
| Q1 2025 | 2024-03-31 | -17.15 | 2025-05-15 | 10-Q |
| FY 2024 | 2023-12-31 | -176.80 | 2025-03-21 | 10-K |
| Q3 2024 | 2023-09-30 | -10.60 | 2024-11-14 | 10-Q |
| Q2 2024 | 2023-06-30 | -17.01 | 2024-08-14 | 10-Q |
| Q1 2024 | 2023-03-31 | -10.52 | 2024-05-15 | 10-Q |
| FY 2023 | 2022-12-31 | -104.32 | 2024-03-25 | 10-K |
| Q3 2023 | 2022-09-30 | -81.00 | 2023-11-14 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.55 | 2023-08-14 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.23 | 2023-05-15 | 10-Q |
| Q1 2022 | 2022-01-31 | -0.23 | 2022-05-16 | 10-Q |
| FY 2022 | 2021-12-31 | -2.43 | 2023-03-31 | 10-K |
| Q3 2022 | 2021-09-30 | -1.96 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.04 | 2022-08-15 | 10-Q |
| Q1 2022 | 2021-03-31 | -0.58 | 2022-05-16 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.